Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12 Week, Double-blind, Randomized, Parallel Group, Multi-center Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren 300 mg and Hydrochlorothiazide 25 mg Compared to Aliskiren 300 mg in Patients With Stage II Hypertension

NCT00705575 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00705575
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00705575 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12 Week, Double-blind, Randomized, Parallel Group, Multi-center Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren 300 mg and Hydrochlorothiazide 25 mg Compared to Aliskiren 300 mg in Patients With Stage II Hypertension
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2008
Completion date
April 30, 2009
Enrollment
688 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension